Reprogramming translation for rare disease therapy: challenges posed by large genes
A recent study published in Nature by Jiang et al. delineates a breakthrough in the treatment of inherited hearing loss through gene therapy. 1 This study offers the most compelling clinical evidence so far that gene replacement therapy can safely restore significant hearing in children with OTOF-related deafness, with benefits lasting up to 2.5 years, setting a new standard for treating inherited sensory disorders.
Authors
- José‐Alain Sahel (ORCID: https://orcid.org/0000-0002-4831-1153)
- Bikash R. Pattnaik
Institutions
- University of Wisconsin–Madison (US)
- University of Pittsburgh (US)
- UPMC Health System (US)
- University of Pittsburgh Medical Center (US)
- Smith-Kettlewell Eye Research Institute (US)
Publication Details
- Journal
- Signal Transduction and Targeted Therapy
- Published
- 2026-08-26
- DOI
- https://doi.org/10.1038/s41392-026-02942-8
- Primary Topic
- CRISPR and Genetic Engineering
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eye and Ear Foundation of Pittsburgh
- Research to Prevent Blindness
- University of Pittsburgh
- Retina Research Foundation